Cardinal Health, Inc. (NYSE:CAH)
The Company is a provider of products and services that improve the safety and productivity of healthcare.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
crunchygeek
(< 20)
Submitted: 1/7/2012 5:40:55 AM :
Start Price:
$41.17
CAH Score:
-3.38
Large presence in academic medical centers
Recs
pchop123
(70.20)
Submitted: 12/30/2011 11:29:12 AM :
Start Price:
$40.88
CAH Score:
-4.02
PE 15.2 and yield of 2.1%
Recs
MajorBob04
(76.26)
Submitted: 10/27/2011 9:29:53 AM :
Start Price:
$42.31
CAH Score:
+6.28
Poor results, not likely to get better, especially if the presidency changes.
Recs
eksummers620
(73.32)
Submitted: 10/19/2011 2:42:05 PM :
Start Price:
$42.10
CAH Score:
-10.97
Soon to be dividend aristocrat.
Recs
mkklaren1968
(60.08)
Submitted: 10/6/2011 12:18:37 AM :
Start Price:
$39.88
CAH Score:
-12.47
Great P/E and P/S, 2% dividend yield. Strong company with a strong future ahead.
Recs
bpkarns
(35.23)
Submitted: 8/14/2011 10:33:15 AM :
Start Price:
$40.85
CAH Score:
-10.21
Company is expanding and acquiring other companies.
Recs
jahartmu
(94.77)
Submitted: 8/4/2011 11:13:05 AM :
Start Price:
$40.96
CAH Score:
-6.68
Betting on an Ohio company that's also a leader in the medical industry. Cardinal should be well-positioned regardless of what happens to Washington's push for socialized medicine.
Recs
XMFConnor
(95.48)
Submitted: 6/6/2011 5:52:47 PM :
Start Price:
$43.69
CAH Score:
-7.74
Einhorn Play
Recs
Recs
dashark44
(96.49)
Submitted: 7/16/2010 1:22:18 PM :
Start Price:
$34.19
CAH Score:
-2.98
Dividend will keep this solid.
Recs
TMFDeej
(99.22)
Submitted: 7/12/2010 7:50:07 AM :
Start Price:
$34.38
CAH Score:
+10.12
Cheap, dividend-paying distributor of drugs and devises to the healthcare industry that's poised to benefit from the government-mandated increase in the number of insured and the coming wave of generic drugs...which are significantly more profitable for distributors.
Deej
Recs
musclemilk13
(98.58)
Submitted: 4/12/2010 3:36:05 PM :
Start Price:
$34.68
CAH Score:
+8.56
4/12 screen #2: percentile and CS
speculating with new screen, high analyst opinion
Recs
havoc315
(98.05)
Submitted: 4/12/2010 2:01:17 PM :
Start Price:
$34.64
CAH Score:
+8.76
A winner from the health care reform
Recs
dnblack
(73.05)
Submitted: 3/5/2010 12:54:36 PM :
Start Price:
$34.00
CAH Score:
+5.18
This is not a screaming deal but with the dividend factored in it looks like they should be priced between $42 and $50. EPS growth is around 3.5% for the past 8 years (with moderate variance), revenue growth is more consistent and around 9.5%.
Their net margin is low, debt is average, return on assets is high.
They compete directly with AmerisourceBergen and McKesson; all three seem to be quality companies with similar performance potential.
Recs
larryknows
(32.22)
Submitted: 3/4/2010 5:19:25 PM :
Start Price:
$33.96
CAH Score:
+4.80
Recession proof niche.
Recs
nmartinov
(< 20)
Submitted: 1/30/2010 2:05:02 PM :
Start Price:
$31.84
CAH Score:
+7.30
Long term buy
Recs
alars79
(69.64)
Submitted: 1/21/2010 11:43:58 AM :
Start Price:
$30.59
CAH Score:
+17.11
New filibuster-proof Congress should reduce the risk of any sweeping health care changes in the near future. Their focus on growing generics would help them remain competitive regardless. Solid ROE, good work being done to increase focus on core competancies, and pharmaceuticals should continue to have recession- and inflation-resistant demand.
Recs
ubber13
(< 20)
Submitted: 11/29/2009 7:16:50 AM :
Start Price:
$30.66
CAH Score:
+13.91
i have bought in at 27.90 and profited from this one.good company a benjamin graham pick. its currently at 12p/e and still a bargain.
Recs
spreadsheetV1
(94.85)
Submitted: 11/23/2009 1:27:23 AM :
Start Price:
$30.78
CAH Score:
+14.72
This met a high level screen to indicate a buy and strong outperform against its peers (other tickers in its industry). My 1st version of this spreadsheet devles deep into the company's balnace sheet and recent income statements, combined with other relevant price data for the company including insider/institutional holdings, short interest, debt levels, etc.
Testing capabilities of this 1st version of my automated, valuation spreadhseet matched with my personal criteria and see how it holds up.
Recs
trdavis33
(77.96)
Submitted: 10/29/2009 2:37:57 PM :
Start Price:
$27.22
CAH Score:
+27.86
They have made significant investments in themselves over the prior 10 years. They meant business and will weather the storm.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 75 : 1 2 3 4 Next »